REV-ERB agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-14. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Repaglinide is an antidiabetic drug in the class of medications known as meglitinides, and was invented in 1983. Repaglinide is a medication used in addition to diet and exercise for blood sugar control in type 2 diabetes. The mechanism of action of repaglinide involves promoting insulin release from β-islet cells of the pancreas; like other antidiabetic drugs, a main side effect concern is hypoglycemia. It is sold by Novo Nordisk under the name of Prandin in the United States, Gluconorm in Canada, Surepost in Japan, Repaglinide in Egypt, and Novonorm elsewhere. In Japan it is produced by Dainippon Sumitomo Pharma.
=== Labeling requirements === For US food and dietary supplement labeling purposes, the amount in a serving is expressed as a percent of Daily Value (%DV). For pantothenic acid labeling purposes, 100% of the Daily Value was 10 mg, but as of May 2016 it was revised to 5 mg to bring it into agreement with the AI. Compliance with the updated labeling regulations was required by January 2020 for manufacturers with US$10 million or more in annual food sales, and by January 2021 for manufacturers with lower volume food sales. A table of the old and new adult daily values is provided at Reference Daily Intake.
Kimon Georgiev became prime minister on 19 May 1934, after the coup d'état. He served as Minister of Foreign Affairs and Religious Affairs (19-23 May 1934) and Minister of Justice (23 May 1934 – 22 January 1935) and temporarily served as Minister of War on 19 May 1934. Kimon Georgiev led the new Cabinet, which was primarily made up of Zveno and Military League representatives. Although they denounced the coup, the other bourgeois parties and the non-fascist bourgeois parties accepted it. The BCP called it a fascist coup, but they were unable to put up a united front to fight it due to mistakes in secretarian doctrine. The coup's perpetrators said in their manifesto that a "national supra-party power" would be established. They abolished the Parliament, dissolved the IMRO, and restructured the governmental apparatus on a fascist basis.
Sources: en.wikipedia.org
The Combine have inspired the creation of several items of merchandise for the Half-Life series. A plush toy was created by Valve, based on the synthetic tripod Hunters introduced in Episode Two. Sold and distributed via Valve's online store, the toy was released in February 2008. In addition, Valve has produced t-shirts depicting the Combine's idea of humanity's evolution, from ape to Combine Overwatch soldier mirroring The March of Progress, and a lithograph displaying twelve pieces of concept art for the Combine soldier. The Combine have received a positive reaction from critics. 1UP.com praised the "epic feel" built up by the Combine and their harsh rule of City 17 in Half-Life 2, stating that this created "a world governed by newspeak, decorated with urban decay, and lacking any hope". GameSpot echoed this praise, saying that the "vision of a dystopian police state is chillingly effective". PC Zone described the appearance of the Combine's soldiers as "Stormtrooper-like". While stating that overall the artificial intelligence for the game was "extremely competent", they expressed the opinion that Combine non-player characters "could have used better survival instincts", citing their reluctance to take cover and tendency to charge at the player and into a shotgun blast. GameSpot noted that their AI had been slightly improved in Episode One.
=== Conservation of mass in mixing calculations === 2H and 1H are stable isotopes. Therefore, the 2H/1H ratio of a pool containing hydrogen, remains constant as long as no hydrogen is added or removed, a property known as conservation of mass. When two pools of hydrogen A and B mix with molar amounts of hydrogen mA and mB, each with their own starting fractional abundance of deuterium (FA and FB), then the fractional abundance of the resulting mixture is given by the following exact equation:
It was thus becoming increasingly evident that the alternative of "democratic rupture" accompanied by "decisive national action" was not viable, so its main supporter, the Communist Party of Spain, decided in March 1976 to change strategy and adopt the alternative of "agreed democratic rupture" advocated by the moderate opposition and the PSOE ─ which had formed the Democratic Convergence Platform ─ although without abandoning the mobilization of citizens to exert continuous pressure on the government and force it to negotiate with the opposition. The change of strategy of the PCE, allowed the merger on March 26 of the two unitary organizations of the opposition, the Junta Democrática and the Plataforma de Convergencia Democrática, which led to the creation of Coordinación Democrática ─ popularly known as Platajunta. In its first manifesto, it rejected the "Arias-Fraga reform" and demanded an immediate political amnesty, full trade union freedom and a "rupture or democratic alternative through the opening of a constituent period". Thus, from the first scenario of rupture with popular uprising, the demand for the calling of general elections from which a constituent process could be derived. Shortly after the Platajunta was formed the government tolerated the socialist trade union Unión General de Trabajadores (UGT) to hold inside the country its XXX Congress camouflaged under the term Jornadas de Estudio (Study Days), but at the same time the police arrested the leader of CC OO, Marcelino Camacho.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.